The influence of CYP2C19 polymorphisms on the pharmacokinetics, pharmacodynamics, and clinical effectiveness of P2Y12 inhibitors

Reviews in Cardiovascular Medicine

Volumn 12, Issue 1, 2011, Pages 1-12

  Price, Matthew J ^a   Tantry, Udaya S ^b   Gurbel, Paul A ^b  

^a SCRIPPS TRANSLATIONAL SCIENCE INSTITUTE   (United States)

^b SINAI CENTER FOR THROMBOSIS RESEARCH   (United States)

Author keywords

Clopidogrel; CYP2C19; Genotype; Pharmacogenomics; Stent; Thrombosis

Indexed keywords

ACETYLSALICYLIC ACID; ACETYLSALICYLIC ACID PLUS CLOPIDOGREL; ADENOSINE DIPHOSPHATE; CLOPIDOGREL; CYTOCHROME P450 2C19; DRUG METABOLITE; MULTIDRUG RESISTANCE PROTEIN 1; PADGEM PROTEIN; PRASUGREL; PROTEIN; PURINERGIC P2Y12 RECEPTOR; TICAGRELOR; UNCLASSIFIED DRUG; VASOPHOSPHOPROTEIN; ANTITHROMBOCYTIC AGENT; CYP2C19 PROTEIN, HUMAN; DRUG DERIVATIVE; PURINERGIC P2Y RECEPTOR ANTAGONIST; TICLOPIDINE; UNSPECIFIC MONOOXYGENASE;

ACUTE CORONARY SYNDROME; AREA UNDER THE CURVE; CARDIOVASCULAR DISEASE; CORONARY ARTERY DISEASE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG INFORMATION; DRUG MECHANISM; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG STRUCTURE; DRUG TRANSFORMATION; ENZYME KINETICS; GENE FREQUENCY; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC RISK; GENETIC VARIABILITY; GENOTYPE; HEART INFARCTION; HETEROZYGOSITY; HUMAN; INDEL MUTATION; LOSS OF FUNCTION MUTATION; MAINTENANCE DRUG DOSE; MAXIMUM PLASMA CONCENTRATION; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; PHARMACODYNAMICS; PHARMACOGENOMICS; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REVIEW; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM; STENT THROMBOSIS; STROKE; THROMBOCYTE AGGREGATION; DRUG COMBINATION; DRUG EFFECT; GENETIC POLYMORPHISM; GENETICS; METABOLISM; PERSONALIZED MEDICINE; PHARMACOGENETICS; PHENOTYPE; TREATMENT OUTCOME;

ARYL HYDROCARBON HYDROXYLASES; ASPIRIN; DRUG THERAPY, COMBINATION; GENOTYPE; HUMANS; INDIVIDUALIZED MEDICINE; PHARMACOGENETICS; PHENOTYPE; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; POLYMORPHISM, GENETIC; PURINERGIC P2Y RECEPTOR ANTAGONISTS; TICLOPIDINE; TREATMENT OUTCOME;

EID: 79957673659     PISSN: 15306550     EISSN: None     Source Type: Journal    
DOI: 10.3909/ricm0590     Document Type: Review

References (48)

1. Yusuf S, Zhao F, Mehta SR, et al Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without st-segment elevation. N Engl J Med. 2001;345:494-502. (Pubitemid 32758501)
2. Mehta SR, Yusuf S, Peters RJ, et al; Clopidogrel in Unstable angina to prevent Recurrent Events trial (CURE) Investigators. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet. 2001;358:527-533. (Pubitemid 32772726)
3. Steinhubl SR, Berger PB, Mann JT 3rd, et al CREDO Investigators. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA. 2002;288:2411-2420. (Pubitemid 35340537)
4. Sabatine MS, Cannon CP, Gibson CM, et al CLARITY-TIMI 28 Investigators. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med. 2005;352:1179-1189. (Pubitemid 40397259)
5. Chen ZM, Jiang LX, Chen YP, et al. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet. 2005;366:1607-1621.
6. Bhatt DL, Flather MD, Hacke W, et al CHARISMA Investigators. Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. J Am Coll Cardiol. 2007;49:1982-1988. (Pubitemid 46694290)
7. Gurbel PA, Bliden KP, Hiatt BL, O'Connor CM. Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation. 2003;107:2908-2913.
8. Bonello L, Tantry US, Marcucci R, et al Working Group on High On-Treatment Platelet Reactivity. Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. J Am Coll Cardiol. 2010;56:919-933.
9. Price MJ, Coleman JL, Steinhubl SR, et al. Onset and offset of platelet inhibition after high-dose clopidogrel loading and standard daily therapy measured by a point-of-care assay in healthy volunteers. Am J Cardiol. 2006;98:681-684. (Pubitemid 44233472)
10. Kazui M, Nishiya Y, Ishizuka T, et al. Identification of the human cytochrome p450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite. Drug Metab Dispos. 2010;38:92-99.
11. Hulot JS, Bura A, Villard E, et al. Cytochrome p450 2c19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects. Blood. 2006;108:2244-2247. (Pubitemid 44497506)
12. Brandt JT, Close SL, Iturria SJ, et al. Common polymorphisms of cyp2c19 and cyp2c9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel. J Thromb Haemost. 2007;5:2429-2436. (Pubitemid 350154353)
13. Mega JL, Close SL, Wiviott SD, et al. Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med. 2009;360:354-362.
14. Kim KA, Park PW, Hong SJ, Park JY. The effect of cyp2c19 polymorphism on the pharmacokinetics and pharmacodynamics of clopidogrel: a possible mechanism for clopidogrel resistance. Clin Pharmacol Ther. 2008;84:236-242.
15. Frère C, Cuisset T, Morange PE, et al. Effect of cytochrome p450 polymorphisms on platelet reactivity after treatment with clopidogrel in acute coronary syndrome. Am J Cardiol. 2008;101:1088-1093.
16. Trenk D, Hochholzer W, Fromm MF, et al. Cytochrome p450 2c19 681g>a polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents. J Am Coll Cardiol. 2008;51:1925-1934. (Pubitemid 351636443)
17. Varenhorst C, James S, Erlinge D, et al. Genetic variation of cyp2c19 affects both pharmacokinetic and pharmacodynamic responses to clopidogrel but not prasugrel in aspirin-treated patients with coronary artery disease. Eur Heart J. 2009;30:1744-1752.
18. Sim SC, Risinger C, Dahl ML, et al. A common novel cyp2c19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants. Clin Pharmacol Ther. 2006;79:103-113. (Pubitemid 43069582)
19. Frère C, Cuisset T, Gaborit B, et al. Cyp2c19*17 allele is associated with better platelet response to clopidogrel in patients admitted for non-ST acute coronary syndrome. J Thromb Haemost. 2009;7:1409-1411.
20. Sibbing D, Koch W, Gebhard D, et al. Cytochrome 2c19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement. Circulation. 2010;121:512-518.
21. Sibbing D, Gebhard D, Koch W, et al. Isolated and interactive impact of common cyp2c19 genetic variants on the antiplatelet effect of chronic clopidogrel therapy. J Thromb Haemost. 2010;8:1685-1693.
22. Tantry US, Bilden KP, Wei C, et al. First analysis of the relation between cyp2c19 genotype and pharmacodynamics in patients treated with ticagrelor versus clopidogrel: the ONSET/OFFSET and RESPOND genotype studies. Circ Cardiovasc Genet. 2010;3:556-566.
23. Shuldiner AR, O'Connell JR, Bilden KP, et al. Association of cytochrome p450 2c19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA. 2009;302:849-857.
24. Simon T, Verstuyft C, Mary-Krause M, et al. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med. 2009;360:363-375.
25. Gurbel PA, Antonino MJ, Tantry US. Recent developments in clopidogrel pharmacology and their relation to clinical outcomes. Expert Opin Drug Metab Toxicol. 2009;5:989-1004.
26. Hulot JS, Collet JP, Silvain J, et al. Cardiovascular risk in clopidogrel-treated patients according to cytochrome p450 2c19*2 loss-of-function allele or proton pump inhibitor coadministration: a systematic meta-analysis. J Am Coll Cardiol. 2010;56:134-143.
27. Mega JL, Simon T, Collet JP, et al. Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis. JAMA. 2010;304:1821-1830.
28. Paré G, Mehta SR, Yusuf S, et al. Effects of cyp2c19 genotype on outcomes of clopidogrel treatment. N Engl J Med. 2010;363:1704-1714.
29. Bhatt DL, Simonsen K, Emison ES. Charisma genomics. Paper presented at: Transcatheter Cardiovascular Therapeutics; September 2009; San Francisco, CA.
30. Wallentin L, James S, Storey RF, et al. Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of tteatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial. Lancet. 2010;376:1320-1328.
31. Mega JL, Close SL, Wiviott SD, et al. Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis. Lancet. 2010;376:1312-1319.
32. Jeong YH, Kim IS, Park Y, et al. Carriage of cytochrome 2C19 polymorphism is associated with risk of high post-treatment platelet reactivity on high maintenance-dose clopidogrel of 150 mg/day: Results of the ACCEL-DOUBLE (Accelerated Platelet inhibition by a Double Dose of Clopidogrel According to Gene Polymorphism) study. JACC Cardiovasc Interv. 2010;3:731-741.
33. Gladding P, Webster M, Zeng I, et al. The pharmacogenetics and pharmacodynamics of clopidogrel response: an analysis from the PRINC (Plavix Response in Coronary Intervention) trial. JACC Cardiovasc Interv. 2008;1:620-627.
34. Williams ET, Jones KO, Ponsler GD, et al. The biotransformation of prasugrel, a new thienopyridine prodrug, by the human carboxylesterases 1 and 2. Drug Metab Dispos. 2008;36:1227-1232. (Pubitemid 351929304)
35. Sugidachi A, Ogawa T, Kurihara A, et al. The greater in vivo antiplatelet effects of prasugrel as compared to clopidogrel reflect more efficient generation of its active metabolite with similar antiplatelet activity to that of clopidogrel's active metabolite. J Thromb Haemost. 2007;5:1545-1551. (Pubitemid 46965386)
36. Mega JL, Close SL, Wiviott SD, et al. Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes. Circulation. 2009;119:2553-2560.
37. Van Giezen J, Nilsson L, Berntsson P, et al. Ticagrelor binds to human P2Y(12) independently from ADP but antagonizes ADP-induced receptor signaling and platelet aggregation. J Thromb Haemost. 2009;7:1556-1565.
38. Montalescot G, Sideris G, Meuleman C, et al. A randomized comparison of high clopidogrel loading doses in patients with non-ST-elevation acute coronary syndromes: the ALBION (Assessment of the Best Loading Dose of Clopidogrel to Blunt Platelet Activation, Inflammation, and Ongoing Necrosis) trial. J Am Coll Cardiol. 2006;48:931-938. (Pubitemid 44292463)
39. Von Beckerath N, Taubert D, Pogatsa-Murray G, et al. Absorption, metabolization, and antiplatelet effects of 300-, 600-, and 900-mg loading doses of clopidogrel: results of the ISAR-CHOICE (Intracoronary Stenting and Antithrombotic Regimen: Choose Between 3 High Oral Doses for Immediate Clopidogrel Effect) trial. Circulation. 2005;112:2946-2950. (Pubitemid 41612296)
40. Aleil B, Jacquemin L, De Poli F, et al. Clopidogrel 150 mg/day to overcome low responsiveness in patients undergoing elective percutaneous coronary intervention: results from the VASP-02 (Vasodilator-Stimulated Phosphoprotein-02) randomized study. JACC Cardiovasc Interv. 2008;1:631-638.
41. Angiolillo DJ, Bernardo E, Palazuelos J, et al. Functional impact of high clopidogrel maintenance dosing in patients undergoing elective percutaneous coronary interventions. Results of a randomized study. Thromb Haemost. 2008;99:161-168.
42. Plavix [package insert]. New York, NY; Bristol-Myers Squibb/Sanofi Pharmaceuticals partnership; 2010.
43. Price MJ, Endemann S, Gollapudi RR, et al. Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation. Eur Heart J. 2008;29:992-1000. (Pubitemid 351844676)
44. Gurbel PA, Bilden KP, Guyer K, et al. Platelet reactivity in patients and recurrent events post-stenting: results of the PREPARE POST-STENTING study. J Am Coll Cardiol. 2005;46:1820-1826. (Pubitemid 41579802)
45. Holmes DR Jr, Dehmer GJ, Kaul S, et al. ACCF/AHA clopidogrel clinical alert: approaches to the FDA "boxed warning": a report of the American College of Cardiology Foundation Task Force on clinical expert consensus documents and the American Heart Association endorsed by the Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons. J Am Coll Cardiol. 2010;56:321-341.
46. Gladding P, White H, Voss J, et al. Pharmacogenetic testing for clopidogrel using the rapid INFINITI analyzer: a dose-escalation study. JACC Cardiovasc Interv. 2009;2:1095-1101.
47. Giusti B, Abbate R. Response to antiplatelet treatment: from genes to outcome. Lancet. 2010;376:1278-1281.
48. Sorrentino BP. Gene therapy to protect haematopoietic cells from cytotoxic cancer drugs. Nat Rev Cancer. 2002;2:431-441. (Pubitemid 37328940)